Gerald Clarke | 10/07/2013
In 2008 and 2009, Genzyme sites were affected by vesivirus infection. This shut down two sites for decontamination. In this candid interview, Lada Laenen, Managing Principal Scientist, Head, Cell Culture and Microbiology, Genzyme, a Sanofi Company, discusses how this affected Genzyme. She explains what they have changed to avoid this happening again. Dr. Laenen also describes the company's creation of an 'organisms of concern' list, ensuring quality i...
To continue reading this story Click Here
RECOMMENDED
The Trust Equation: Why Transparency Defines the Future Winners in Contract Manufacturing
2025-12-17
Upcoming Events
Pharma Contract Manufacturing
23 - 25 March 2026
Mercure Hotel MOA Berlin, Germany
Register Now |
View Agenda |
Learn More